Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$254.19
+5.27%
Alpha Vantage · 11/6/2026
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
+29.0%
3 months
+325.0%
6 months
+367.7%
1 year
+944.8%
Year to date
+762.0%
52-week range
$22.36 – $258.38
Latest reported period: Sep 30, 2026
Market cap
$102.85B
P/E
-36.9
P/B
15
P/S
40.7
Revenue
$2.53B
Net income
-$2.79B
Diluted EPS
-7.1
Gross margin
28.00%
Net margin
-110.50%
Return on equity
-37.60%
Total debt
$4.18B
Cash
$1.2B
Free cash flow
-$2.04B
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 30, 2026 | $1.31B | $162M | 75.80% | 12.30% | -$1.68B |
| Jun 30, 2026 | $145M | -$782M | 35.90% | -539.30% | -$563M |
| Mar 31, 2026 | $389M | -$1.34B | -145.50% | -345.20% | -$692M |
| Dec 31, 2025 | $678M | -$826M | 33.30% | -121.80% | $891M |
| Sep 30, 2025 | $1.02B | -$200M | 79.60% | -19.70% | -$880M |
| Jun 30, 2025 | $142M | -$825M | 16.20% | -581.00% | -$922M |
| Mar 31, 2025 | $108M | -$971M | 16.70% | -899.10% | -$1.16B |
| Dec 31, 2024 | $966M | -$1.12B | 23.50% | -115.90% | $303M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
StoreSubscribeSign InMy SubscriptionsFounder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer CenterMy Stock ListsEmail PreferencesHelp & SupportSign OutSearch stocks or...
Original sourceSubscribe to CNBC PROSubscribe to Investing ClubLicensing & ReprintsCNBC CouncilsJoin the CNBC PanelDigital ProductsNews ReleasesClosed CaptioningCorrectionsAbout CNBCInternshipsSite...
Original sourceSubscribe to CNBC PROSubscribe to Investing ClubLicensing & ReprintsCNBC CouncilsJoin the CNBC PanelDigital ProductsNews ReleasesClosed CaptioningCorrectionsAbout CNBCInternshipsSite...
Original sourcewatch nowModerna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum and Covid vaccine revenue...
Original sourceSupport WBURModerna and Merck recently released remarkable new results of the personalized cancer vaccine.Here & Now's Scott Tong speaks with Matthew Herper, a senior writer at STAT, the health and...
Original sourceSubscribe to CNBC PROSubscribe to Investing ClubLicensing & ReprintsCNBC CouncilsJoin the CNBC PanelDigital ProductsNews ReleasesClosed CaptioningCorrectionsAbout CNBCInternshipsSite...
Original sourceAdam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The...
Original sourceU.S. stock futures tracked mixed overnight late on Sunday, as last week's sharp selloff in technology stocks weighed on the Nasdaq even as markets brace for crucial earnings updates.As of 10:20 p.m. EDT, Dow futures gained 0.22%, and S&P 500 futures were up 0.11%. Nasdaq-100 futures were down 0.02...
Original source